Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review

Most patients with advanced/metastatic hormone receptor-positive, HER2-negative breast cancer receive first-line therapy with cycline-dependent kinase 4/6 inhibitors plus endocrine therapy. Almost universally, these patients eventually progress due to the emergence of resistant cancer clones. Target...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Maria Rosaria Valerio, Daniela Sambataro, Federica Martorana, Martina Greco, Chiara Mesi, Vittorio Gebbia, Paolo Vigneri, Giuseppa Scandurra
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2026-03-01
Rangatū:	Current Oncology
Ngā marau:	capivasertib fulvestrant hormone positive breast cancer AKT PI3K mTOR
Urunga tuihono:	https://www.mdpi.com/1718-7729/33/4/198
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!